Combivir (AZT/3TC)
| Brand Name: |
Combivir |
| Generic Name: |
Zidovudine and lamivudine, AZT and 3TC |
| Adult Single Dose: |
One tablet containing 300 mg AZT and 150 mg 3TC
(twice a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- An Overview of Combivir (AZT/3TC) (June 10, 2011)
From AIDSinfo
- Combivir (Zidovudine + Lamivudine) (May 26, 2011)
To read PDF, click here.
From AIDS InfoNet
- Combivir (March/April 2010)
To read PDF, click here.
In Positively Aware, from Test Positive Aware Network
- Patient Information About Combivir (AZT/3TC) (PDF) (2009)
From GlaxoSmithKline
- Combivir (AZT + Epivir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Combivir (AZT/3TC) (October 19, 2006)
From AIDS Treatment Data Network
- Drug Interactions: Combivir (August 2004)
[Archived Article]
From Project Inform
- GlaxoSmithKline Alerts Patients, Pharmacists and Physicians to Watch for Third-Party Tampering That Incorrectly Labels Ziagen as Combivir (May 10, 2002)
[Archived Article]
From U.S. Food and Drug Administration
- FDA Approves First Combination Drug for AIDS (September 29, 1997)
[Archived Article]
Combivir (combination of zidovudine and lamivudine) receives traditional approval for treating AIDS and HIV infection.
From U.S. Food and Drug Administration
News
Research
- Switching From Zidovudine/Lamivudine to Tenofovir/Emtricitabine: Results of an Uncontrolled Cohort (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
- Zidovudine/Lamivudine Inferior as First-Line NRTI Backbone (August 15, 2006)
In XVI International AIDS Conference
- In Head-to-Head International Study, Tenofovir + Emtricitabine Bests Zidovudine/Lamivudine in Tolerability and Convenience (July 27, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- No K65R Mutations in Patients Failing Tenofovir + Emtricitabine (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Incidence of Zidovudine-Associated Anemia May Be Lower Than Initially Thought -- Particularly With Fixed-Dose Combinations (July 26, 2005)
[Archived Article]
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Aurobindo Receives Tentative FDA Approval to Produce Generic Version of Combivir for PEPFAR (July 11, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Aurobindo Pharma Receives Tentative FDA Approval to Produce Generic Stavudine for PEPFAR (July 5, 2005)
[Archived Article]
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Addition of Short-Course Zidovudine/Lamivudine to Single-Dose Nevirapine Decreases Development of Maternal NNRTI-Resistant HIV (July 15, 2004)
[Archived Article]
In The XV International AIDS Conference, from The Body PRO
- U.S. Approves Emtriva; Gilead Hopes Viread/Emtriva Combo Will Compete With Combivir (July 3, 2003)
[Archived Article]
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Trizivir-Only Arm Closed in PI-Sparing, Naive Therapy Trial (March 10, 2003)
[Archived Article]
Important interim results from a Phase III, randomized, double-blind comparison of three protease-inhibitor-sparing regimens for the initial treatment of HIV infection (AACTG Protocol A5095).
To read PDF, click here.
From U.S. National Institute of Allergy and Infectious Diseases
- Adherence to Combivir as Post-Exposure Prophylaxis in Non-Occupational HIV Exposures (July 8, 2002)
[Archived Article]
In The XIV International AIDS Conference, from The Body PRO
- Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
[Archived Article]
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The Compact Quad, Combivir/Abacavir/Efavirenz -- Preliminary 48-Week Results (October 27, 2001)
[Archived Article]
In 39th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Abacavir/Combivir Is Comparable to Indinavir/Combivir in HIV-1 Infected Antiretroviral Therapy Naive Adults: Preliminary Results of a 48-Week Open-Label Study (CNA3014) (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Metabolic and Anthropometric Changes Observed in HIV-Infected Patients Treated With Combivir (ZDV/3TC) Plus Nelfinavir or Nevirapine (A Substudy of the COMBINE Study) (July 10, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- The PI-Sparing Compact Quad Regimen of Combivir (COM)/Abacavir (ABC)/Efavirenz (EFV) Is Potent and Well-Tolerated in Antiretroviral Therapy (ART) Naive Subjects With High Viral Loads: 24-Wk Data (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Final 12-Month Results From the COMBINE Study: A Randomized, Open, Multicenter Trial Comparing Combivir Plus Nelfinavir or Nevirapine in Naive Patients (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- A Randomized Open Label Study to Investigate Abacavir and Lamivudine as Once-Daily Components of a Triple-Combination Regimen (July 9, 2001)
[Archived Article]
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Comparison of a Triple Combination Regimen Containing an Enteric-Coated Formulation of Didanosine Administered Once Daily Versus a Regimen of Combivir Plus Nelfinavir (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Efficacy of Combivir (COM) (Lamivudine 150 mg/Zidovudine 300 mg) Plus Ziagen (Abacavir (ABC) 300 mg) BID Compared to Trizivir (TZV) (3TC 150 mg/ZDV 300 mg/ABC 300 mg) BID in Patients Receiving Prior COM Plus ABC (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Time to Appearance of NRTI-Associated Mutations and Response to Subsequent Therapy for Patients on Failing ABC/COM (February 6, 2001)
[Archived Article]
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Studies Suggest AZT/3TC/Abacavir May Offer Adequate Potency (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
- NZT4002: 64-week Analysis of Combivir (COM)-Based Triple and Quadruple Therapy in Antiretroviral-Naive, HIV-1-Infected Subjects (July 12, 2000)
[Archived Article]
In The XIII International AIDS Conference, from The Body PRO
|
|
Advertisement
|
Email
Glossary
